Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis

Brain Research

Volumn 1472, Issue , 2012, Pages 138-148

  Campbell, Anna M ^a   Zagon, Ian S ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Astroctyes; Behavior; MOG induced disease; Multiple sclerosis; Opioid growth factor; Opioid growth factor receptor; Proliferation

Indexed keywords

ENKEPHALINAMIDE[2 METHIONINE 5 PROLINE]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROPEPTIDE; OPIOID GROWTH FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GAIT DISORDER; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; SPINAL CORD; T LYMPHOCYTE;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENKEPHALIN, METHIONINE; FEMALE; MICE; MICE, INBRED C57BL; PAIN THRESHOLD; SPINAL CORD;

MUS;

EID: 84865686979     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.07.006     Document Type: Article

References (30)

1. M. Axelsson, C. Malmestrom, S. Nilsson, S. Haghighi, L. Rosengren, and J. Lycke Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis J. Neurol. 258 2011 882 888
2. P. Bannerman, and A. Hahn Enhanced visualization of axon pathology in EAE using thy1-YFP transgenic mice J. Neurol. Sci. 260 2007 23 32
3. P. Bannerman, A. Hahn, A. Soulika, V. Gallo, and D. Pleasure Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia Glia 55 2007 57 64
4. J.L. Bennett, and O. Stuve Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications Clin. Neuropharmacol. 32 2009 121 132
5. F. Cheng, P.J. McLaughlin, M.F. Verderame, and I.S. Zagon The OGF-OGFr axis utilizes the p16 (INK4a) and p21 (WAF1/CIP1) pathways to restrict normal cell proliferation Mol. Biol. Cell 20 2009 319 327
6. F. Cheng, P.J. McLaughlin, M.F. Verderame, and I.S. Zagon Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation Exp. Biol. Med. 234 2009 532 541
7. 5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation Am. J. Physiol. 299 2010 R774 R785
8. F. Cheng, P.J. McLaughlin, and I.S. Zagon Regulation of cell proliferation by the opioid growth factor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking Exp. Biol. Med. 235 2010 1093 1101
9. J. Das Sarma, L.W. Kenyon, S.T. Hingley, and K.S. Shindler Mechanisms of primary axonal damage in a viral model of multiple sclerosis J. Neurosci. 29 2009 10272 10280
10. R.N. Donahue, P.J. McLaughlin, and I.S. Zagon Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model Exp. Biol. Med. 236 2011 1036 1050
11. A.M. Ercolini, and S.D. Miller Mechanisms of immunopathology in murine models of central nervous system demyelinating disease J. Immunol. 176 2006 3293 3298
12. M. Forte, B.G. Gold, G. Marracci, P. Chaudhary, E. Basso, D. Johnsen, X. Yu, J. Fowlkes, M. Rahder, K. Stem, P. Bernardi, and D. Bourdette Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis Proc. Natl. Acad. Sci. USA 104 2007 7558 7563
13. Y. Gilgun-Sherki, H. Panet, V. Holdengreber, R. Mosberg-Galili, and D. Offen Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis Neurosci. Res. 47 2003 201 207
14. P. Gourdain, C. Ballerini, A.B. Nicot, and C. Carnaud Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: evidence for a critical role of the central nervous system J. Neuroinflammation 9 2012 25
15. L. Jasmin, G. Janni, T.M. Moallem, D.A. Lappi, and P.T. Ohara Schwann cells are removed from the spinal cord after effecting recovery from paraplegia J. Neurosci. 20 2000 9215 9223
16. E.E. McCandless, Q.L. Wang, B.M. Woerner, J.M. Harper, and R.S. Klein CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis J. Immunol. 177 2006 8053 8064
17. K.A. Rahn, P.J. McLaughlin, and I.S. Zagon Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis Brain Res. 1381 2011 243 253
18. S.A. Rizvi, and M.A. Agius Current approved options for treating patients with multiple sclerosis Neurology 63 2004 S8 S14
19. A. Van der Walt, H. Butzkueven, S. Kolbe, M. Marriott, E. Alexandrou, M. Gresle, G. Egan, and T. Kilpatrick Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade Pharmacol. Ther. 126 2010 82 93
20. H.L. Weiner The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65 2009 239 248
21. I.S. Zagon, R.N. Donahue, R.H. Bonneau, and P.J. McLaughlin B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: implication of the treatment of autoimmune diseases Immunobiology 216 2011 173 183
22. 5]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases Immunobiology 216 2011 579 590
23. I.S. Zagon, D.M. Gibo, and P.J. McLaughlin Ontogeny of zeta, the opioid growth factor receptor, in rat brain Brain Res. 596 1992 149 156
24. I.S. Zagon, T. Isayama, and P.J. McLaughlin Preproenkephalin mRNA expression in the developing and adult rat brain Mol. Brain Res. 21 1994 85 98
25. I.S. Zagon, and P.J. McLaughlin Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma - a role for endogenous opioid systems in cancer Life Sci. 35 1984 409 416
26. I.S. Zagon, and P.J. McLaughlin Endogenous opioids regulate growth of neural tumor cells in culture Brain Res. 490 1989 14 25
27. I.S. Zagon, and P.J. McLaughlin Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system Brain Res. 542 1991 318 323
28. I.S. Zagon, K.A. Rahn, R.H. Bonneau, A.P. Turel, and P.J. McLaughlin Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis Brain Res. 1310 2010 154 161
29. I.S. Zagon, K.A. Rahn, A.P. Turel, and P.J. McLaughlin Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradign for the treatment of multiple sclerosis Exp. Biol. Med. 234 2009 1383 1392
30. I.S. Zagon, M.F. Verderame, and P.J. McLaughlin The biology of the opioid growth factor receptor (OGFr) Brain Res. Rev. 38 2002 351 376